Journal
TRENDS IN PARASITOLOGY
Volume 25, Issue 9, Pages 423-431Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.pt.2009.05.011
Keywords
-
Categories
Funding
- Biotechnology and Biological Sciences Research Council
- NIH [AI54711-02]
- PI Dr Chris King
- Center for Global Health Diseases
- Case Western Reserve University, Cleveland, OH, USA
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054711] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A recombinant antigen vaccine against Schistosoma mansoni remains elusive, in part because the parasite deploys complex defensive and offensive strategies to combat immune attack. Nevertheless, research on rodent and primate models has shown that schistosomes can be defeated when appropriate responses are elicited. Acquired protection appears to involve protracted inhibition of larval migration or key molecular processes at the adult surfaces, not rapid cytolytic killing mechanisms. A successful vaccine will likely require a cocktail of antigens rather than a single recombinant protein. In addition, ways need to be found of keeping the immune system on permanent alert, either to achieve adequate inhibition of protein function in adults, or because a trickle of incoming parasites does not amplify the secondary response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available